FDA approves temporary import of sodium bicarbonate injection due to shortage
The Food and Drug Administration recently authorized the temporary import of a sodium bicarbonate injection product from Australia to address a critical shortage of the drug, commonly used in hospitals to treat a chemical imbalance in the blood. Athenex Pharmaceutical Division will import and distribute the drug in 10 mL and 100 mL vials. Pfizer recently reported shortages of several injectable drugs used in hospitals and other clinical settings, including sodium bicarbonate injection and emergency drug syringes. FDA is working with manufacturers to resolve these and other injectable drug shortages.
Related News Articles
Headline
The Food and Drug Administration and Baxter provided an update on efforts Baxter and other companies have taken to reduce the risk of shortages of…
Headline
Baxter Healthcare Corp., in coordination with the Food and Drug Administration, has agreed to temporarily import certain intravenous drug products, such…
Headline
In the wake of Hurricane Maria, the Food and Drug Administration is working to avoid critical shortages of drugs made in Puerto Rico, which is home to dozens…
Headline
Hospira, a Pfizer company, has voluntarily recalled certain lots of 8.4% sodium bicarbonate injection and other emergency syringe drugs distributed since…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will host a June 8 webinar on strategies to…
Headline
The U.S. norepinephrine shortage in 2011 was associated with increased mortality among hospital patients with septic shock, according to a study published…